Two breast cancer drugs get NHS approval

November 17, 2017, Cancer Research UK
Two breast cancer drugs get NHS approval
Credit: Cancer Research UK

Two breast cancer drugs have been recommended for use by the NHS in England.

In draft guidance, the National Institute for Health and Care Excellence (NICE) has approved palbociclib (Ibrance) and ribociclib (Kisqali) for with advanced .

The drugs are thought to slow the growth of the disease and delay the need for other treatments.

Cancer Research UK – who funded the Nobel Prize-winning researchers whose work underpinned the drugs' development – welcomed the announcement. Rose Gray, senior policy advisor at the charity, said:

"These decisions have taken some time, but we're pleased that the Government and NICE are taking steps to streamline the process so that patients can access life-saving drugs more quickly," she said.

The approval comes after NICE agreed confidential price deals for the drugs. It had previously rejected palbociclib because its cost was too high in relation to its clinical effectiveness.

The drugs can now be given to patients with late stage breast cancer that is classified based on certain molecules being present or absent from the surface of the cancer cells. This type of breast cancer is called hormone sensitive or hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative disease.

The approval comes despite uncertainties about how long the drugs extend overall survival.

NICE looked at either drug taken with another kind of treatment called an aromatase inhibitor, for patients who hadn't been treated for their .

It found that both drugs stalled the growth of the cancer for an extra 10 months on average.

NICE concluded that it was likely that this would result in some improvement in overall survival, although this wasn't certain from available clinical trial results.

There have been calls for NICE to continue to evaluate based on how effective they are in NHS patients, and for this to contribute to drug pricing decisions.

By slowing down the advance of the cancer, the drugs can delay the need for chemotherapy, giving women the chance to live their regular life for longer. The two drugs work in a similar way and are given once daily.

The drugs are the first of a new type that slows the progression of cancer by switching off two molecules called CDK 4 and 6. Aromatase inhibitors work by blocking the production of the hormone oestrogen, stopping its ability to fuel some breast cancers.

Professor Carole Longson, director of the centre for health technology evaluation at NICE, said the approvals committee heard from patient experts that delaying the progression of their cancer for as long as possible was highly valued.

Longson added that by postponing disease progression the drugs "may reduce the number of people who are exposed to the often unpleasant side effects of chemotherapy, and delay the need for its use in others".

"We are pleased therefore that the companies have been able to agree reductions to the price."

Professor Nicholas Turner, who led clinical trials of palbociclib at The Institute of Cancer Research, London and the Royal Marsden, said the drugs have made a huge difference to women's lives.

"These drugs have allowed women to live a normal life for longer," he said.

There are around 45,000 new diagnoses of each year in England. It is estimated that around 8,000 people in England would be eligible for treatment with either each year.

Explore further: Breast cancer drug not recommended for use in England

Related Stories

Breast cancer drug not recommended for use in England

September 4, 2017
The drug fulvestrant (Faslodex) has not been recommended in England to treat late stage breast cancer, in draft guidance.

Promising immunotherapy drug now available for some lung cancer patients in England

September 21, 2017
Some lung cancer patients in England can now be offered a potentially life-extending immunotherapy drug.

Breast cancer drug approved for NHS England

June 16, 2017
The drug trastuzumab emtansine (Kadcyla) will soon be routinely available for patients in England with an advanced type of breast cancer.

Some cancer drugs approved in Europe might not have sufficient evidence of survival benefits, says study

October 6, 2017
Most cancer drugs approved in Europe from 2009-2013 weren't backed by sufficient scientific evidence that they work, according to a new study.

Palbociclib efficacious in metastatic breast cancer

November 17, 2016
(HealthDay)—Palbociclib can help slow the progression of advanced breast cancer, according to a study published in the Nov. 17 issue of the New England Journal of Medicine.

Drug combination slows breast cancer spread

March 2, 2016
A combination of two drugs delays progression of advanced, aggressive breast cancer by an average of nine months - working in all subsets of the most common type of breast cancer.

Recommended for you

Magnetized wire could be used to detect cancer in people, scientists report

July 16, 2018
A magnetic wire used to snag scarce and hard-to-capture tumor cells could prove to be a swift and effective tactic for early cancer detection, according to a study by researchers at the Stanford University School of Medicine.

Researchers suggest new treatment for rare inherited cancers

July 16, 2018
Studying two rare inherited cancer syndromes, Yale Cancer Center (YCC) scientists have found the cancers are driven by a breakdown in how cells repair their DNA. The discovery, published today in Nature Genetics, suggests ...

Researchers map 'family trees' of acute myeloid leukemia

July 16, 2018
For the first time, a team of international researchers has mapped the family trees of cancer cells in acute myeloid leukaemia (AML) to understand how this blood cancer responds to a new drug, enasidenib. The work also explains ...

Looking at the urine and blood may be best in diagnosing myeloma

July 13, 2018
When it comes to diagnosing a condition in which the plasma cells that normally make antibodies to protect us instead become cancerous, it may be better to look at the urine as well as the serum of our blood for answers, ...

Massive genome havoc in breast cancer is revealed

July 12, 2018
In cancer cells, genetic errors wreak havoc. Misspelled genes, as well as structural variations—larger-scale rearrangements of DNA that can encompass large chunks of chromosomes—disturb carefully balanced mechanisms that ...

Study shows biomarker panel boosts lung cancer risk assessment for smokers

July 12, 2018
A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon smoking history, capturing risk for people who have ever smoked, not only for heavy smokers, an international ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.